Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphoma

News
Video

Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.

Bijal D. Shah, MD, of the Moffit Cancer Center, discussed the encouraging signs in the early stages of data collection regarding CAR T-cell therapy and mantle cell lymphoma at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida from December 7-10.

Transcription:
Wow I can’t tell you how excited I am about the CAR T data and mantle cell lymphoma. This was a highly refractory population, meaning they had seen BTK now progressing. In our own series of patients, that group of patients had a median survival of somewhere around 2 to 4 months.

High overall response rates, durable remissions at a year, and without any mortality attributed to the CAR T-cell therapy. This is a big deal. For patients with proliferative mantle cell lymphoma, for patients with p53 variant mantle cell lymphoma we desperately need active therapies. And its early, we’ve only seen the first data cut for the abstract, but this preliminary signal of activity is so encouraging. To answer your question ‘is it practice changing,’ absolutely. I can’t imagine that Kite Gilead is not knocking on the FDA’s door right now.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content